Back to search

Article

Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World Study

2023-08-10

Abstract excerpt

<h4>Background: </h4> Research on bevacizumab combined with EGFR-TKIs is limited to erlotinib, and the NCCN guidelines only recommend erlotinib combined with bevacizumab as a nonfirst-line option. Consequently, To address the real-world efficacy of various treatment regimens, we conducted this study. Methods A total of 11,893 patients were screened. The patients were divided into three distinct groups: single tar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9f338387-e121-5924-9f31-f21933187311
DOI
10.21203/rs.3.rs-3238070/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudyDOI 10.21203/rs.3.rs-3238070/v1
Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingSemantic proximity
Real-Life Use of First-Generation EGFR-TKI with Chemotherapy in EGFR-sensitive Mutations in Non-Small-Cell Lung Cancer: A Single-Center Analysis and Meta-AnalysisSemantic proximity
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidenceSemantic proximity
First- Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup AnalysisSemantic proximity
First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup AnalysisSemantic proximity
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.Semantic proximity
[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].Semantic proximity
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.Semantic proximity
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.Semantic proximity
Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)Semantic proximity
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.Semantic proximity
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity
Select a neighboring publication to make it the new centre.